October Term 2022 · Docket 21-757
Does a patent claim covering all antibodies binding to a specific protein target require proof that every single one is easy to make?
Amgen argues its broad patent claim is valid because it provides a general roadmap. Sanofi argues the claim is invalid because it covers antibodies that are difficult to create.